Editing Maprotiline (section)

==History==
Maprotiline was developed by [[Ciba-Geigy|Ciba]] (now operated by [[Novartis]]).<ref name="pmid19557250">{{cite journal | vauthors = Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K | title = Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters | journal = Chemical Communications | issue = 25 | pages = 3677–3692 | date = July 2009 | pmid = 19557250 | doi = 10.1039/b903035m }}</ref> It was patented in 1966 and was first described in the literature in 1969.<ref name="pmid19557250" /> The drug was introduced for medical use in 1974.<ref name="pmid19557250" /><ref name="Dart2004">{{cite book| vauthors = Dart RC | chapter = Chapter 134: Cyclic Antidepressant Drugs |title=Medical Toxicology| chapter-url = https://books.google.com/books?id=BfdighlyGiwC&pg=PA836|year=2004|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-2845-4|pages=836–}}</ref> [[Generic drug|Generics]] are now widely available. It was introduced after most of the other TCAs but was the first TeCA to be developed and marketed, with the TeCAs [[mianserin]] and [[amoxapine]] following shortly thereafter and [[mirtazapine]] being introduced later on.<ref name="pmid19557250" /><ref name="Dart2004" />